Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
Paclitaxel (Taxol) is formulated in 50% Cremophor EL (CrEL)/absolute ethanol for clinical use. In order to reduce vehicle-related side effects, Genetaxyl was developed to have paclitaxel formulated in a solution containing lesser amounts of CrEL and ethanol plus 2 other solvents. The purpose of the study was to evaluate the efficacy and safety of Genetaxyl as first-line therapy to treat breast cancer patients. Patients with newly diagnosed stage III (N = 8) or IV (N = 10), or recurrent (N = 11) breast cancer received single-agent Genetaxyl at 175 mg/m(2) administered in a 3-h infusion every 3 weeks for 3-6 cycles. A total of 148 cycles were delivered to 29 patients. The overall response rate was 41.4% (95% confidence interval, 23.4 to 59.2%), and that of patients with metastatic disease (N = 20) was 30%. Median survival for all patients was 32.4 months and 24.3 months for patients having metastatic disease. The toxicity profile seems favorable, especially regarding myelosuppression and myalgia/arthralgia. No severe hypersensitivity reaction occurred. These phase II trial results demonstrate that a 60% reduction of CrEL by Genetaxyl's formulation does not affect the activity of paclitaxel and could allow for better control of several CrEL-related toxicities.
Chao
Ta-Chung
TC
Division of Medical Oncology, Department of Medicine, Taipei Veteran General Hospital, Taipei 112, Taiwan, R.O.C..
Chu
Zyting
Z
Tseng
Ling-Ming
LM
Chiou
Tzeon-Jye
TJ
Hsieh
Ruey-Kuen
RK
Wang
Wei-Shu
WS
Yen
Chueh-Chuan
CC
Yang
Muh-Hwa
MH
Hsiao
Liang-Tsai
LT
Liu
Jin-Hwang
JH
Chen
Po-Min
PM
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002626:Chemistry, Pharmaceutical; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel
J Clin Oncol. 1994 Dec;12(12):2654-66
7989941
J Clin Oncol. 2003 Mar 15;21(6):976-83
12637460
Med J Aust. 1997 May 19;166(10):520-3
9196484
Semin Oncol. 1996 Oct;23 (5 Suppl 11):6-10
8893892
Control Clin Trials. 1989 Mar;10(1):1-10
2702835
Clin Cancer Res. 1998 Oct;4(10):2321-9
9796961
Eur J Cancer. 1996 Jan;32A(1):47-51
8695240
Cancer Res. 1990 Jul 15;50(14):4199-203
2364376
Clin Cancer Res. 1998 Aug;4(8):1937-42
9717822
Br J Cancer. 1999 Sep;81(2):330-5
10496361
Ann Pharmacother. 2001 Sep;35(9):1114-7
11573863
Eur J Cancer. 2001 Sep;37(13):1590-8
11527683
Invest New Drugs. 2001 May;19(2):125-41
11392447
Gynecol Oncol. 2002 Mar;84(3):420-5
11855881
Semin Oncol. 1996 Feb;23(1 Suppl 1):4-9
8629036
Cancer. 1981 Jan 1;47(1):207-14
7459811
Cancer Res. 1996 May 1;56(9):2112-5
8616858
Cancer Res. 1999 Apr 1;59(7):1454-7
10197613
Ann Pharmacother. 1994 May;28(5 Suppl):S11-4
7915152